Issue 34, 2024

A novel tumor theranostic strategy based on metabolic glycoengineering and disulfidptosis

Abstract

Traditional metabolic glycoengineering involves participation of a monofunctional unnatural monosaccharide. To broaden the application boundary of this powerful technique, a bifunctional molecule, Ac4ManNSSN3, is designed and applied for a tumor theranostic strategy in this work. The results from both cell and animal experiments show good in situ tumor detection and tumor inhibition effects.

Graphical abstract: A novel tumor theranostic strategy based on metabolic glycoengineering and disulfidptosis

Supplementary files

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Communication
Submitted
19 Jun 2024
Accepted
01 Aug 2024
First published
02 Aug 2024

Org. Biomol. Chem., 2024,22, 6946-6949

A novel tumor theranostic strategy based on metabolic glycoengineering and disulfidptosis

J. Li, H. Chang, P. Zhang, L. Hou, W. Li, Y. Zhang and Z. Lao, Org. Biomol. Chem., 2024, 22, 6946 DOI: 10.1039/D4OB01027B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements